Renin-angiotensin system and cardiovascular risk

Lancet

Volumn 369, Issue 9568, 2007, Pages 1208-1219

  Schmieder, Roland E ^a   Hilgers, Karl F ^a   Schlaich, Markus P ^a   Schmidt, Bernhard MW ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; ROSIGLITAZONE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

BIOLOGY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; ENZYME ACTIVITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 34047121150     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60242-6     Document Type: Review

References (151)

1. Tigerstedt R., and Bergman P. Niere und Kreislauf. Scand Arch Physiol 8 (1898) 223-271
2. Admiraal P., Derkx F., Danser A., Pieterman H., and Schalekamp M. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 15 (1990) 44-55
3. Paul M., Wagner J., and Dzau V. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 91 (1993) 2058-2064
4. Danser A. Local renin-angiotensin systems. Mol Cell Biochem 157 (1996) 211-216
5. Urata H., Kinoshita A., Misono K., Bumpus F., and Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265 (1990) 22348-22357
6. Saris J., van Dijk M., Kroon I., Schalekamp M., and Danser A. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 35 (2000) 764-768
7. Koka V., Wang W., Huang X., Kim-Mitsuyama S., Truong L., and Lan H. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 113 (2006) 1353-1360
8. Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000) E1-E9
9. Ferrario C. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47 (2006) 515-521
10. de Gasparo M., Catt K., Inagami T., Wright J., and Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
11. Carey R. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45 (2005) 840-844
12. Imai Y., Kuba K., Rao S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436 (2005) 112-116
13. Wolf G., Wenzel U., Burns K., Harris R., Stahl R., and Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 61 (2002) 1986-1995
14. Esteban V., Lorenzo O., Ruperez M., et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15 (2004) 1514-1529
15. Chai S., Fernando R., Peck G., et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 61 (2004) 2728-2737
16. Esteban V., Ruperez M., Sanchez-Lopez E., et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 96 (2005) 965-973
17. Danser A., and Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 46 (2005) 1069-1076
18. Kostenis E., Milligan G., Christopoulos A., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111 (2005) 1806-1813
19. Santos R., Simoes e Silva A., Maric C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003) 8258-8263
20. Tallant E., Ferrario C., and Gallagher P. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289 (2005) H1560-H1566
21. Xiao H., Fuchs S., Campbell D., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165 (2004) 1019-1032
22. Crackower M., Sarao R., Oudit G., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
23. Li W., Moore M., Vasilieva N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-504
24. Zisman L., Keller R., Weaver B., et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 108 (2003) 1707-1712
25. Lieb W., Graf J., Gotz A., et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med 84 (2006) 88-96
26. Stoll M., Steckelings U., Paul M., Bottari S., Metzger R., and Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95 (1995) 651-657
27. AbdAlla S., Lother H., Abdel-tawab A., and Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276 (2001) 39721-39726
28. Li J., Culman J., Hortnagl H., et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. Faseb J 19 (2005) 617-619
29. Kohlstedt K., Brandes R., Muller-Esterl W., Busse R., and Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 94 (2004) 60-67
30. Hilgers K., Veelken R., Muller D., et al. Renin uptake by the endothelium mediates vascular angiotensin formation. Hypertension 38 (2001) 243-248
31. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., and Sraer J. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109 (2002) 1417-1427
32. Burckle C., Jan Danser A., Muller D., et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 47 (2006) 552-556
33. Alderman M., Madhavan S., Ooi W., Cohen H., Sealey J., and Laragh J. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 (1991) 1098-1104
34. Campbell D., Woodward M., Chalmers J., et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 112 (2005) 110-206
35. Campbell D., Aggarwal A., Esler M., and Kaye D. beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 358 (2001) 1609-1610
36. Brunner H., and Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 359 (2002) 990-992
37. Linz W., Wiemer G., Gohlke P., Unger T., and Scholkens B. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47 (1995) 25-49
38. Campbell D., Krum H., and Esler M. Losartan increases bradykinin levels in hypertensive humans. Circulation 111 (2005) 315-320
39. Azizi M., Rousseau A., Ezan E., et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97 (1996) 839-844
40. Azizi M., Webb R., Nussberger J., and Hollenberg N. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 24 (2006) 243-256
41. Gradman A., Schmieder R., Lins R., Nussberger J., Chiang Y., and Bedigian M. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
42. Levy D., Garrison R., Savage D., Kannel W., and Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
43. Mancia G., Zanchetti A., Agabiti-Rosei E., et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 95 (1997) 1464-1470
44. Schmieder R. The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 20 (2005) 2610-2612
45. Rizzoni D., Muiesan M., Porteri E., et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32 (1998) 985-992
46. Schmieder R., Langenfeld M., Friedrich A., Schobel H., Gatzka C., and Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 94 (1996) 1304-1309
47. Klingbeil A., Schobel H., Langenfeld M., Hilgers K., Schaufele T., and Schmieder R. Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects. J Hypertens 17 (1999) 825-833
48. Schlaich M., Schobel H., Langenfeld M., Hilgers K., and Schmieder R. Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol 49 (1998) 153-159
49. Jones A., Dhamrait S., Payne J., et al. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension 42 (2003) 500-506
50. Schmieder R., Erdmann J., Delles C., et al. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 37 (2001) 175-182
51. Mazzolai L., Pedrazzini T., Nicoud F., Gabbiani G., Brunner H., and Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35 (2000) 985-991
52. Galzerano D., Tammaro P., del Viscovo L., et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 18 (2005) 1563-1569
53. Klingbeil A., Schneider M., Martus P., Messerli F., and Schmieder R. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
54. Dahlof B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
55. Devereux R., Dahlof B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
56. Verdecchia P., Angeli F., Borgioni C., et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 16 (2003) 895-899
57. Kannel W., Wolf P., Benjamin E., and Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82 (1998) 2N-9N
58. Wattigney W., Mensah G., and Croft J. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108 (2003) 711-716
59. Verdecchia P., Reboldi G., Gattobigio R., et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 41 (2003) 218-223
60. Wachtell K., Hornestam B., Lehto M., et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 705-711
61. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
62. Schmeider R., Kjeldsen S., Julius S., McInnes G., Zanchetti A., and Hua T. Reduced incidence of new onset atrial fibrillatin with angiotensin II receptor blockade: the Value-trial. J Hypertens 24 suppl 1 (2006) 53
63. Ehrlich J., Hohnloser S., and Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27 (2006) 512-518
64. Healey J., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
65. Madrid A., Bueno M., Rebollo J., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
66. Boos C., Anderson R., and Lip G. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 27 (2006) 136-149
67. Boos C., and Lip G. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 19 (2005) 855-859
68. Gavras I., and Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens 13 (2000) 512-517
69. Engelmann M., and Svendsen J. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26 (2005) 2083-2092
70. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
71. Dernellis J., and Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25 (2004) 1100-1107
72. Lewington S., Clarke R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
73. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
74. Groth W., Blume A., Gohlke P., Unger T., and Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 21 (2003) 2175-2182
75. Sigmund C., and Davisson R. Targeting brain AT1 receptors by RNA interference. Hypertension 47 (2006) 145-146
76. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 291 (1985) 97-104
77. PROGRESS collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
78. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
79. Kjeldsen S., Dahlof B., Devereux R., et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
80. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
81. Schrader J., Luders S., Kulschewski A., et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
82. Williams B., Lacy P., Thom S., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
83. Hosomi N., Nishiyama A., Ban C., et al. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 134 (2005) 225-231
84. Boring L., Gosling J., Cleary M., and Charo I. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
85. Libby P., Ridker P., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
86. Ridker P., Rifai N., Stampfer M., and Hennekens C. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
87. Wassmann S., Stumpf M., Strehlow K., et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94 (2004) 534-541
88. Schieffer B., Luchtefeld M., Braun S., Hilfiker A., Hilfiker-Kleiner D., and Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87 (2000) 1195-1201
89. Rabbani R., and Topol E. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 41 (1999) 402-417
90. Takagishi T., Murahashi N., Azagami S., Morimatsu M., and Sasaguri Y. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem Mol Biol Int 35 (1995) 265-273
91. Kranzhofer R., Browatzki M., Schmidt J., and Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 257 (1999) 826-828
92. Pastore L., Tessitore A., Martinotti S., et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 100 (1999) 1646-1652
93. Pueyo M., Gonzalez W., Nicoletti A., Savoie F., Arnal J., and Michel J. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20 (2000) 645-651
94. Dandona P., Kumar V., Aljada A., et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 88 (2003) 4496-4501
95. Chen H., Li D., Saldeen T., Phillips M., and Mehta J. Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits. Biochem Biophys Res Commun 282 (2001) 474-479
96. Martin G., Dol F., Mares A., et al. Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol 43 (2004) 191-199
97. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
98. Griendling K., Minieri C., Ollerenshaw J., and Alexander R. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
99. Beckman J., and Koppenol W. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
100. Nickenig G., Sachinidis A., Michaelsen F., Bohm M., Seewald S., and Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 95 (1997) 473-478
101. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 340 (1999) 115-126
102. Warnholtz A., Nickenig G., Schulz E., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
103. John S., Delles C., Klingbeil A., Jacobi J., Schlaich M., and Schmieder R. Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. J Hypertens 17 (1999) 1933-1939
104. Vane J., Anggard E., and Botting R. Regulatory functions of the vascular endothelium. N Engl J Med 323 (1990) 27-36
105. Halcox J., Schenke W., Zalos G., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 (2002) 653-658
106. Schachinger V., Britten M., and Zeiher A. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
107. Suwaidi J., Hamasaki S., Higano S., Nishimura R., Holmes Jr. D., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
108. Heitzer T., Schlinzig T., Krohn K., Meinertz T., and Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
109. Neunteufl T., Heher S., Katzenschlager R., et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 86 (2000) 207-210
110. Griendling K., and Alexander R. Oxidative stress and cardiovascular disease. Circulation 96 (1997) 3264-3265
111. Dzau V., Bernstein K., Celermajer D., et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88 (2001) 1L-20L
112. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
113. Bahlmann F., de Groot K., Mueller O., Hertel B., Haller H., and Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45 (2005) 526-529
114. Mancini G., Henry G., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94 (1996) 258-265
115. Antony I., Lerebours G., and Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 94 (1996) 3115-3122
116. Klingbeil A., John S., Schneider M., Jacobi J., Handrock R., and Schmieder R. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 16 (2003) 123-128
117. Hornig B., Landmesser U., Kohler C., et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103 (2001) 799-805
118. Modena M., Bonetti L., Coppi F., Bursi F., and Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40 (2002) 505-510
119. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
120. Fox K. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
121. Braunwald E., Domanski M., Fowler S., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
122. Jandeleit-Dahm K., Tikellis C., Reid C., Johnston C., and Cooper M. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23 (2005) 463-473
123. Carlsson P., Berne C., and Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41 (1998) 127-133
124. Kampf C., Lau T., Olsson R., Leung P., and Carlsson P. Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts. Diabetologia 48 (2005) 1159-1167
125. Benson S., Pershadsingh H., Ho C., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
126. Schupp M., Lee L., Frost N., et al. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 47 (2006) 586-589
127. Abuissa H., Jones P., Marso S., and O'Keefe Jr. J. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
128. Gillespie E., White C., Kardas M., Lindberg M., and Coleman C. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28 (2005) 2261-2266
129. Kjeldsen S., Julius S., Mancia G., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24 (2006) 1405-1412
130. DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med 355 (2006) 1608-1610
131. Dinneen S., and Gerstein H. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157 (1997) 1413-1418
132. Hillege H., Fidler V., Diercks G., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
133. European Society for Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
134. Zhang Y., Lee E., Devereux R., et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 47 (2006) 410-414
135. de Zeeuw D., Remuzzi G., Parving H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
136. Ibsen H., Olsen M., Wachtell K., et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45 (2005) 198-202
137. Ruggenenti P., Fassi A., Ilieva A., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
138. Strippoli G., Craig M., Schena F., and Craig J. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 16 (2005) 3081-3091
139. Parving H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
140. Brenner B., Cooper M., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
141. Lewis E., Hunsicker L., Clarke W., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
142. Pourdjabbar A., Lapointe N., and Rouleau J. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?. Can J Cardiol 18 suppl A (2002) 7A-14A
143. de Zeeuw D., Remuzzi G., Parving H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
144. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355 (2000) 253-259
145. Lindholm L., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
146. Hou F., Zhang X., Zhang G., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006) 131-140
147. Remuzzi G., Ruggenenti P., Perna A., et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15 (2004) 3117-3125
148. Barnett A., Bain S., Bouter P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004) 1952-1961
149. Ruggenenti P., Perna A., Gherardi G., Benini R., and Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35 (2000) 1155-1165
150. Suissa S., Hutchinson T., Brophy J., and Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 69 (2006) 913-919
151. Estacio R., Jeffers B., Gifford N., and Schrier R. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 suppl 2 (2000) B54-B64